Can the dextroenantiomer of the aromatase inhibitor fadrozole be useful for clinical investigation of aldosterone-synthase inhibition?

Journal of Hypertension

Volumn 24, Issue 6, 2006, Pages 993-997

  Ménard, Joël ^a,b   Pascoe, Leigh ^c  

^a SPIM   (France)

^b INSERM   (France)

^c FONDATION JEAN DAUSSET CEPH   (France)

Author keywords

Aldosterone synthase; Cardiovascular disease; Dextroenanitomer; Fadrozole

Indexed keywords

ALDOSTERONE ANTAGONIST; ALDOSTERONE SYNTHASE; ALDOSTERONE SYNTHASE INHIBITOR; AMILORIDE; ANASTROZOLE; AROMATASE INHIBITOR; CGS 20286; CGS 20287; CYTOCHROME P450 INHIBITOR; EPLERENONE; EXEMESTANE; FAD 286A; FADROZOLE; LETROZOLE; NAPHTHALENE DERIVATIVE; POTASSIUM; SODIUM CHLORIDE; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE ACTIVITY; BLOOD VESSEL; BREAST TENSION; CLINICAL RESEARCH; DECISION MAKING; DEXTRO ENANTIOMER; DRUG APPROVAL; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG RESEARCH; DRUG SELECTIVITY; DRUG SPECIFICITY; ENANTIOMER; ENZYME INHIBITION; EXPERIMENTAL MEDICINE; EXPERIMENTAL MODEL; GENOMICS; GYNECOMASTIA; HEART; HEART PROTECTION; HUMAN; HYPERTENSION; IMPOTENCE; KIDNEY; MENSTRUATION DISORDER; NONHUMAN; PAINFUL GYNECOMASTIA; PRIORITY JOURNAL; REVIEW; SALT INDUCED HYPERTENSION;

EID: 33646824898     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000226183.98439.b3     Document Type: Review

References (73)

1. Laragh JH. Potassium, angiotensin and the dual control of aldosterone secretion. N Engl J Med 1973; 289:745-747.
2. Williams GH. Essential hypertension as an endocrine disease. Endocrinol Metab Clin North Am 1994; 23:429-444.
3. Berger S, Bleich M, Schmid W, Greger R, Schutz G. Mineralocorticoid receptor knockout mice: lessons on Na+ metabolism. Kidney Int 2000; 57:1295-1298.
4. Edwards CR, Stewart PM, Burt D, Brett L, McIntyre MA, Sutanto WS, et al. Localisation of 11 beta-hydroxysteroid dehydrogenase - tissue specific protector of the mineralocorticoid receptor. Lancet 1988; 2:986-989.
5. White PC. Disorders of aldosterone biosynthesis and action. N Engl J Med 1994; 331:250-258.
6. White PC, Curnow KM, Pascoe L. Disorders of steroid 11 beta-hydroxylase isozymes. Endocr Rev 1994; 15:421-438.
7. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 1992; 120:893-901.
8. Robert V, Silvestre JS, Charlemagne D, Sabri A, Trouve P, Wassef M, et al. Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension 1995; 26:971-978.
9. Takeda Y. Vascular synthesis of aldosterone: role in hypertension. Mol Cell Endocrinol 2004; 217:75-79.
10. Ahmad N, Romero DG, Gomez-Sanchez EP, Gomez-Sanchez CE. Do human vascular endothelial cells produce aldosterone? Endocrinology 2004; 145:3626-3629.
11. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, et al. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 1998; 273:4883-4891.
12. Gomez-Sanchez EP, Ahmad N, Romero DG, Gomez-Sanchez CE. Origin of aldosterone in the rat heart. Endocrinology 2004; 145:4796-4802.
13. Nishikawa T, Suematsu S, Saito J, Soyama A, Ito H, Kino T, Chrousos G. Human renal mesangial cells produce aldosterone in response to low-density lipoprotein (LDL). J Steroid Biochem Mol Biol 2005; 96:309-316.
14. Ngarmukos C, Grekin RJ. Nontraditional aspects of aldosterone physiology. Am J Physiol Endocrinol Metab 2001; 281:E1122-E1127.
15. Chun TY, Pratt JH. Non-genomic effects of aldosterone: new actions and questions. Trends Endocrinol Metab 2004; 15:353-354.
16. Wehling M. Specific, nongenomic actions of steroid hormones. Annu Rev Physiol 1997; 59:365-393.
17. Oberleithner H. Aldosterone makes human endothelium stiff and vulnerable. Kidney Int 2005; 67:1680-1682.
18. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341:709-717.
19. Rocha R, Martin-Berger CL, Yang P, Scherrer R, Delyani J, McMahon E. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002; 143:4828-4836.
20. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348:1309-1321.
21. Campbell SE, Janicki JS, Matsubara BB, Weber KT. Myocardial fibrosis in the rat with mineralocorticoid excess.Prevention of scarring by amiloride. Am J Hypertens 1993; 6:487-495.
22. Sepehrdad R, Chander PN, Oruene A, Rosenfeld L, Levine S, Stier CT Jr. Amiloride reduces stroke and renal injury in stroke-prone hypertensive rats. Am J Hypertens 2003; 16:312-318.
23. Muller-Vieira U, Angotti M, Hartmann RW. The adrenocortical tumor cell line NCI-H295R as an in vitro screening system for the evaluation of CYP11B2 (aldosterone synthase) and CYP11B1 (steroid-11 beta-hydroxylase) inhibitors. J Steroid Biochem Mol Biol 2005; 96:259-270.
24. Bureik M, Hubel K, Dragan CA, Scher J, Becker H, Lenz N, Bernhardt R. Development of test systems for the discovery of selective human aldosterone synthase (CYP11B2) and 11beta-hydroxylase (CYP11B1) inhibitors. Discovery of a new lead compound for the therapy of congestive heart failure, myocardial fibrosis and hypertension. Mol Cell Endocrinol 2004; 217:249-254.
25. Wells SA Jr, Santen RJ, Lipton A, Haagensen DE Jr, Ruby EJ, Harvey H, Dilley WG. Medical adrenalectomy with aminoglutethimide: clinical studies in postmenopausal patients with metastatic breast carcinoma. Ann Surg 1978; 187:475-484.
26. Steele RE, Mellor LB, Sawyer WK, Wasvary JM, Browne LJ. In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A. Steroids 1987; 50:147-161.
27. Schieweck K, Bhatnagar AS, Matter A. CGS 16949A, a new nonsteroidal aromatase inhibitor: effects on hormone-dependent and -independent tumors in vivo. Cancer Res 1988; 48:834-838.
28. Trunet PF, Bhatnagar AS, Chaudri HA, Hornberger U. Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients. Acta Oncol 1996; 35 (Suppl. 5):15-18.
29. Trunet PF, Vreeland F, Royce C, Chaudri HA, Cooper J, Bhatnagar AS. Clinical use of aromatase inhibitors in the treatment of advanced breast cancer. J Steroid Biochem Mol Sci 1997; 61:241-245.
30. Buzdar AU. A summary of second-line randomized studies of aromatase inhibitors. J Steroid Biochem Mol Biol 2001; 79:109-114.
31. Lamberts SW, Bruining HA, Marzouk H, Zuiderwijk J, Uitterlinden P, Blijd JJ, et al. The new aromatase inhibitor CGS-16949A suppresses aldosterone and cortisol production by human adrenal cells in vitro. J Clin Endocrinol Metab 1989; 69:896-901.
32. Demers LM, Melby JC, Wilson TE, Lipton A, Harvey HA, Santen RJ. The effects of CGS 16949A, an aromatase inhibitor on adrenal mineralocorticoid biosynthesis. J Clin Endocrinol Metab 1990; 70:1162-1166.
33. Trunet PF, Mueller P, Girard F, Aupetit B, Bhatnagar AS, Zognbi F, et al. The effects of fadrozole hydrochloride on aldosterone secretion in healthy male subjects. J Clin Endocrinol Metab 1992; 74:571-576.
34. Furet P, Batzl C, Bhatnagar A, Francotte E, Rihs G, Lang M. Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds. J Med Chem 1993; 36:1393-1400.
35. Khodarahmi GA, Laughton CA, Smith HJ, Nicholls PJ. Enantioselectivity of some 1-[(benzofuran-2-yl) phenylmethyl] imidazoles as aromatase (P450AROM) inhibitors. J Enzyme Inhib 2001; 16:401-416.
36. Francotte E, Cherkaoui S, Faupel M. Separation of the enantiomers of some racemic nonsteroidal aromatase inhibitors and barbiturates by capillary electrophoresis. Chirality 1993; 5:516-526.
37. Veldhuis JD, Melby JC. Isolated aldosterone deficiency in man: acquired and inborn errors in the biosynthesis or action of aldosterone. Endocr Rev 1981; 2:495-517.
38. Zennaro MC, Borensztein P, Jeunemaitre X, Armanini D, Corvol P, Soubrier F. Molecular characterization of the mineralocorticoid receptor in pseudohypoaldosteronism. Steroids 1995; 60:164-167.
39. Pascoe L, Curnow KM, Slutsker L, Rosler A, White PC. Mutations in the human CYP11B2 (aldosterone synthase) gene causing corticosterone methyloxidase II deficiency. Proc Natl Acad Sci U S A 1992; 89:4996-5000.
40. White PC. Aldosterone synthase deficiency and related disorders. Mol Cell Endocrinol 2004; 217:81-87.
41. Sartorato P, Lapeyraque AL, Armanini D, Kuhnle U, Khaldi Y, Salomon R, et al. Different inactivating mutations of the mineralocorticoid receptor in fourteen families affected by type I pseudohypoaldosteronism. J Clin Endocrinol Metab 2003; 88:2508-2517.
42. Kagawa CM, Sturtevant FM, Van Arman CG. Pharmacology of a new steroid that blocks salt activity of aldosterone and deoxycorticosterone. J Pharmacol Exp Ther 1959; 126:123-130.
43. Menard J, Gonzalez MF, Guyene TT, Bissery A. Investigation of aldosterone-synthase inhibition in rats. J Hypertens 2006; 24:1147-1155.
44. Fiebeler A, Nussberger J, Shagdarsuren E, Rong S, Hilfenhaus G, Al-Saadi N, et al. Aldosterone synthase inhibitor ameliorates angiotensin II-induced organ damage. Circulation 2005; 111:3087-3094.
45. Ramsay L, Harrison I, Shelton J, Tidd M. Relative potency of prorenoate and spironolactone in normal man. Clin Pharmacol Ther 1975; 18:391-400.
46. Ulmschneider S, Muller-Vieira U, Mitrenga M, Hartmann RW, Oberwinkler-Marchais S, Klein CD, et al. Synthesis and evaluation of imidazolylmethylenetetrahydronaphthalenes and imidazolylmethyleneindanes: potent inhibitors of aldosterone synthase. J Med Chem 2005; 48:1796-1805.
47. Voets M, Antes I, Scherer C, Muller-Vieira U, Biemel K, Barassin C, et al. Heteroaryl-substituted naphthalenes and structurally modified derivatives: selective inhibitors of CYP11B2 for the treatment of congestive heart failure and myocardial fibrosis. J Med Chem 2005; 48:6632-6642.
48. Fischer A, Borensztein P, Roussel C. The European rare diseases therapeutic initiative. PLoS Med 2005; 2:e243.
49. Jeunemaitre X, Chatellier G, Kreft-Jais C, Charru A, DeVries C, Plouin PF, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol 1987; 60:820-825.
50. de Gasparo M, Joss U, Ramjoue HP, Whitebread SE, Haenni H, Schenkel L, et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987; 240:650-656.
51. de Gasparo M, Whitebread SE, Preiswerk G, Jeunemaitre X, Corvol P, Menard J. Antialdosterones: incidence and prevention of sexual side effects. J Steroid Biochem 1989; 32:223-227.
52. Pratt JH, Eckert GJ, Newman S, Ambrosius WT. Blood pressure responses to small doses of amiloride and spironolactone in normotensive subjects. Hypertension 2001; 38:1124-1129.
53. Saha C, Eckert GJ, Ambrosius WT, Chun TY, Wagner MA, Zhao Q, Pratt JH. Improvement in blood pressure with inhibition of the epithelial sodium channel in blacks with hypertension. Hypertension 2005; 46:481-487; discussion 469-470.
54. Lifton RP, Dluhy RG, Powers M, Rich GM, Cook S, Ulick S, Lalouel JM. A chimaeric 11 beta-hydroxylase/aldosterone synthase gene causes glucocorticoid-remediable aldosteronism and human hypertension. Nature 1992; 355:262-265.
55. Litchfield WR, Anderson BF, Weiss RJ, Lifton RP, Dluhy RG. Intracranial aneurysm and hemorrhagic stroke in glucocorticoid-remediable aldosteronism. Hypertension 1998; 31:445-450.
56. Brown JJ, Davies DL, Ferriss JB, Fraser R, Haywood E, Lever AF, Robertson JI. Comparison of surgery and prolonged spironolactone therapy in patients with hypertension, aldosterone excess, and low plasma renin. BMJ 1972; 2:729-734.
57. Irony I, Kater CE, Biglieri EG, Shackleton CH. Correctable subsets of primary aldosteronism Primary adrenal hyperplasia and renin responsive adenoma. Am J Hypertens 1990; 3:576-582.
58. Kaplan NM. Cautions over the current epidemic of primary aldosteronism. Lancet 2001; 357:953-954.
59. Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, Pessina AC. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996; 27:1039-1045.
60. Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45:1243-1248.
61. Ramsay LE, Silas JH, Freestone S. Diuretic treatment of resistant hypertension. BMJ 1980; 281:1101-1103.
62. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 2002; 40:892-896.
63. Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003; 16:925-930.
64. Laragh JH, Sealey JE. K(+) depletion and the progression of hypertensive disease or heart failure. The pathogenic role of diuretic-induced aldosterone secretion. Hypertension 2001; 37:806-810.
65. Smith NL, Lemaitre RN, Heckbert SR, Kaplan RC, Tirschwell DL, Longstreth WT, Psaty BM. Serum potassium and stroke risk among treated hypertensive adults. Am J Hypertens 2003; 16:806-813.
66. Thibonnier M, Marchetti J, Corvol P, Menard J, Milliez P. Abnormal regulation of antidiuretic hormone in idiopathic edema. Am J Med 1979; 67:67-73.
67. Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N, et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351:33-41.
68. Giebisch G. Renal potassium transport: mechanisms and regulation. Am J Physiol 1998; 274:F817-F833.
69. Kayes-Wandover KM, Schindler RE, Taylor HC, White PC. Type 1 aldosterone synthase deficiency presenting in a middle-aged man. J Clin Endocrinol Metab 2001; 86:1008-1012.
70. Tobian L, Lange J, Ulm K, Wold L, Iwai J. Potassium reduces cerebral hemorrhage and death rate in hypertensive rats, even when blood pressure is not lowered. Hypertension 1985; 7:I110-I114.
71. Funder JW. Relative aldosterone excess: relative to what? Hypertension 2005; 46:643-644.
72. Stowasser M, Sharman J, Leano R, Gordon RD, Ward G, Cowley D, Marwick TH. Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab 2005; 90:5070-5076.
73. Gordon RD, Laragh JH, Funder JW. Low renin hypertensive states: perspectives, unsolved problems, future research. Trends Endocrinol Metab 2005; 16:108-113.